cytoplasmic polyadenylation element binding protein 4Genealiases: CPE-BP4 · hCPEB-4
Q-omics provides the consensus-scored CPEB4 profile across patient tissues and cancer cell-line models. CPEB4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CPEB4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, CPEB4 RNA expression shows 20,242 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where CPEB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPEB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPEB4 survival associations across molecular data types. CPEB4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPEB4 RNA expression–survival associations across cancer types. High CPEB4 expression shows unfavorable associations in UVM and BLCA, but favorable associations in KIRC, SKCM, ACC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CPEB4 RNA expression.
This table summarizes CPEB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CPEB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPEB4 shows lower tumor expression in THCA, KIRC, LUSC, HNSC, BLCA and COAD. The THCA box plot shows higher CPEB4 RNA expression in normal versus tumor tissue (log2 FC = −1.501, t-test p < 0.001).
This table shows molecular features associated with CPEB4 in patient tissues and cancer cell lines. In patient samples, CPEB4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CPEB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
